*Corresponding author:
Yolanda Bryce, Memorial Sloan Kettering Cancer Center, New York, USAReceived: November 21, 2018; Published: December 20, 2018
DOI: 10.26717/BJSTR.2018.12.002509
To view the Full Article Peer-reviewed Article PDF
Chronic Venous Disease (CVD) affects more than 25 million people with 20% of patients developing the most severe form of disease of large gaping nonhealing leg wounds with skin break down and exudative ulceration (Figure 1) [1,2]. CVD is caused by irreversible damage to the venous valves (one-way valves that promote the one-way flow of blood from the legs to the heart and inhibit blood from pooling at the ankles and causing venous hypertension) leading to varicose veins, leg pain, swelling and leg ulcers and wounds [2]. Risk factors include prior Deep Venous Thrombosis (DVT), hereditary disorder, prolonged standing/sitting, and obesity [2]. The prognosis of venous ulcers is poor with delayed healing and recurrence. Annually, an estimated $3 billion are spent in the treatment of chronic venous wounds [3].
Abbreviations : CT: Computed Tomography; ICA: Internal Carotid Artery; MRI: Magnetic Resonance Imaging; VZV: Varicella Zoster Virus; HSV: Herpex Simple Virus; CSF: Cerebro Spinal Fluid
Mini Review| Conclusion| References|
International Association of Landscape Archaeology, Czech Glass Society, Czech Republic
Department of Chemistry, Semenov Institute of Chemical Physics, USSR Academy of Sciences, Moscow, Russia
Pharmaco-kinetics, dynamics and Drug Metabolism, Touro College of Pharmacy, USA
Professor of Nuclear Medicine, Faculty of Medicine and Surgery, University of Milan, Milan, Italy
Associate Professor at Department of Breast and Thyorid Surgey, Chongqing General Hospital, China